Feedback
Settings

Settings

Goto Application

1,896,693 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 189,670
1.WO/2026/101847METHODS OF INFLUENZA VACCINATION AND COMPOSITIONS FOR THE SAME
WO - 15.05.2026
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/US2025/053858 Applicant BLUEWILLOW BIOLOGICS, INC. Inventor KALICHARRAN, Kishna
The present invention relates to compositions and methods for inducing a robust cross-strain immune protection against influenza infection in a subject. The methods comprise administering a prime-boost combination of vaccines intranasally and intramuscularly, wherein at least one of the administered vaccines is a nanoemulsion influenza vaccine.
2.WO/2026/101937COMPOSITIONS COMPRISING (Z)-ENDOXIFEN AND A CDK4/6 INHIBITOR AND METHODS OF USE THEREOF
WO - 15.05.2026
Int.Class A61K 31/138
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
 Appl.No PCT/US2025/054057 Applicant ATOSSA THERAPEUTICS, INC. Inventor QUAY, Steven Carl
The present disclosure relates to compositions and methods for treating hormone receptor positive (HR+) cancer with (Z)-endoxifen and a CDK4/6 inhibitor, such as abemaciclib. The disclosure is based on the discovery that (Z)-endoxifen and abemaciclib have synergistic effects on reducing tumor growth and proliferation in breast cancer models. The disclosure also provides fixed dose combinations of (Z)-endoxifen and abemaciclib, which offers advantages in terms of convenience and compliance. The compositions and methods are suitable for treating subjects with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer, especially those who are contraindicated for aromatase inhibitor therapy and/or ovarian suppression therapy.
3.WO/2026/102147TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS
WO - 15.05.2026
Int.Class C07D 417/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14containing three or more hetero rings
 Appl.No PCT/US2025/054404 Applicant TREELINE BIOSCIENCES, INC. Inventor HORN, Evan J.
protein. These compounds are useful, for example, for treating a cancer in a subject (e.g., a human). This disclosure also provides compositions comprising the compounds of Formula (I), (II), (III), (IV), (V), or (VI), or pharmaceutically acceptable salts thereof, provided herein as well as methods of using and making the same.
4.WO/2026/102237ARTIFICIAL EXPRESSION CONSTRUCTS FOR MODULATING GENE EXPRESSION IN ASTROCYTES FOR THE ASSESSMENT AND/OR TREATMENT OF EPILEPTIC DISORDERS
WO - 15.05.2026
Int.Class C12N 15/864
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
864Parvoviral vectors
 Appl.No PCT/US2025/054539 Applicant ALLEN INSTITUTE Inventor GORE, Bryan
Artificial expression constructs for modulating gene expression in targeted central nervous system cell types are described. The artificial expression constructs can be used in the assessment and/or treatment of epileptic disorders.
5.WO/2026/102252COMPOSITION AND METHOD FOR MODULATING MICROBIOMES WITH POSTBIOTIC FERMENTS
WO - 15.05.2026
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
 Appl.No PCT/US2025/054563 Applicant KIMBERLY-CLARK WORLDWIDE, INC. Inventor QUIRK, Stephen
spp. bacteria to prevent dysbiosis and other related conditions and infections.
6.WO/2026/102297ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE
WO - 15.05.2026
Int.Class A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
 Appl.No PCT/US2025/054619 Applicant STUART, William Inventor STUART, William
Disclosed herein are antibody-oligonucleotide conjugates, pharmaceutical compositions, and methods for treating Sickle Cell Disease. The disclosure contemplates compositions and methods capable of binding a human hematopoietic stem cell marker conjugated to an oligonucleotide capable of hybridizing a target sequence. In some embodiments, the target sequence is a BCL11A transcript sequence. In some embodiments of the disclosure, the antibody-oligonucleotide conjugate promotes antisense- and/or RNA interference-mediated inhibition of BCL11A.
7.WO/2026/102462ENGINEERED CELLS FOR TREATING DIABETES
WO - 15.05.2026
Int.Class A61K 35/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
48Reproductive organs
54Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
545Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
 Appl.No PCT/US2025/055010 Applicant CITY OF HOPE Inventor YEE, Jiing-Kuan
, genetically engineered human pluripotent stem cells, beta cells derived from genetically engineered human pluripotent stem cells, compositions, and cell aggregates, and methods of treating diabetes. The human pluripotent stem cells and beta cells provided herein including embodiments thereof may be genetically modified to express exogenous genes and/or inactivate endogenous genes.
8.WO/2026/099042ORAL CARE COMPOSITION
WO - 15.05.2026
Int.Class A61Q 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
11Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastes; Mouth rinses
 Appl.No PCT/EP2025/081266 Applicant UNILEVER IP HOLDINGS B.V. Inventor CHANDRASEKARAN, Sembian
An oral care composition comprising: a) a pigment having a hue angle, h, in the CIELAB system of from 220 to 320 degrees; b) a dye having a different colour to that of the pigment.
9.WO/2026/099117PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 ANALOG AND AN INORGANIC MESOPOROUS MATERIAL
WO - 15.05.2026
Int.Class A61K 9/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
 Appl.No PCT/EP2025/081670 Applicant MERCK PATENT GMBH Inventor MUELLER, Lena
The present invention relates to pharmaceutical compositions comprising a therapeutic peptide having a molecular weight between 1 kDa and 100 kDa dispersed in an inorganic mesoporous material, said inorganic mesoporous material being in particular mesoporous silica.
10.WO/2026/099477DOSING OF OLIGONUCLEOTIDE DRUGS FOR INHALATION
WO - 15.05.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/EP2025/082448 Applicant RNATICS GMBH Inventor RABE, Klaus F.
The present invention relates to a formulation comprising an oligonucleotide drug which is an antagonist of microRNA-21 as an active agent for administration to a human subject in need thereof by inhalation.
# -